Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Grand Pharma’s Global Innovative Product STC3141 Achieved the Clinical Endpoint of The Phase Ib Clinical Trial for the Treatment of ARDS in China

  • According to the data analysis of the clinical trial, in the primary endpoint of the study, STC3141 did not suggest any potential serious safety problems or unexpected results in the overall safety profile, showing favorable safety and tolerance;
  • In the analysis of the secondary endpoint of efficacy, STC3141 showed positive signals compared with standard treatment method in terms of alleviating the severity of ARDS, improving the prognosis of ARDS patients, helping ARDS patients to be weaned off the ventilator and shortening the ICU length of stay;
  • The Phase IIa clinical study of STC3141 for the treatment of severe COVID-19 patients conducted in Europe has also achieved its clinical endpoint, with no serious drug-related adverse reactions, and the patients were well tolerated.

    HONG KONG SAR - Media OutReach - 31 October 2022 - Grand Pharmaceutical Group Limited ("Grand Pharma", stock code: 00512) announced that that the global innovative drug STC3141 in the field of severe disease, which is developed by its wholly-owned subsidiary Grand Medical Pty Ltd (an innovative drug R&D center set up by Grand Pharma in Australia), has successfully achieved the clinical study endpoint of the phase Ib clinical trial for the treatment of acute respiratory distress syndrome ("ARDS") in China ("NCT05000671").

    NCT05000671 is a randomized, double-blind, placebo-controlled Phase Ib clinical study for investigating and evaluating the safety, tolerability and pharmacokinetics of the drug in patients with ARDS. The study received clinical approval for conducting clinical study from the National Medical Products Administration of the People's Republic of China (NMPA) in March 2021 and completed the first patient enrollment in October, enrolled all patients in July 2022, and completed all follow-up and data analysis recently. A total of 16 evaluable subjects were enrolled in the study. All patients received standard intensive care unit ("ICU") supported treatment and care appropriate to their conditions, adopting the principle of continuous 72-hour intravenous administration and dose-escalation grouped dosing. Subjects in each group were continuously observed until the 28th day after receiving treatment.

    According to the data analysis of the clinical trial, in the primary endpoint of the study, STC3141 did not suggest any potential serious safety problems or unexpected results in the overall safety profile, showing favorable safety and tolerance. Meanwhile, in the analysis of the secondary endpoint of efficacy, STC3141 showed positive signals compared with standard treatment method in terms of alleviating the severity of ARDS, improving the prognosis of ARDS patients, helping ARDS patients to be weaned off the ventilator and shortening the ICU length of stay. It provides a solid foundation for further clinical research of the product.

    ARDS is one of the main causes of death in ICU patients, and currently there is no effective medication treatment method in clinical practice. According to a statistical data related to nearly 30,000 patients in 459 ICUs of 50 countries around the world, the prevalence of ARDS is approximately 10.4% in critically ill patients, the overall mortality rate is approximately 34% in hospital, and mortality rate is approximately 60% in severe patients. In addition, among patients with severe COVID-19, ARDS is also one of the main causes of death, indicating an urgent clinical demand and tremendous market prospect.

    STC3141 is a global innovative small molecule compound with a new mechanism of action independently developed by Grand Pharma. It can reverse the organ damage caused by the body's excessive immune response by neutralizing extracellular free histones and neutrophil traps, and can be used for a variety of severe indications. The relevant preclinical research results of the product have been published in the top academic journal "Nature Communications" in February 2020, which has far-reaching academic influence.

    In terms of clinical research, in addition to the Phase Ib clinical study for the treatment of ARDS patients conducted in China, the Phase IIa clinical study of STC3141 for the treatment of severe COVID-19 patients conducted in Europe has also achieved its clinical endpoint, with no serious drug-related adverse reactions, and the patients were well tolerated. Moreover, the product has approved to conduct Phase Ib clinical studies for the treatment of sepsis in Australia in May 2020 and in Belgium in April 2022, respectively, comprehensively promoting the international multi-center clinical trials.

    Grand Pharma commented, "The achievement of the clinical endpoint in the Phase Ib clinical study in China of this project is not only an important milestone in the Group's global clinical research process, but also provide solid data support for the subsequent clinical development of the product. In the future, the Group will continue to adopt the R&D concept of independent R&D and global expansion to create a full-cycle management product cluster for chronic airway diseases and a pipeline of anti-infection products for severe diseases, so as to continuously strengthen the Group's industry position in this field."

    Hashtag: #GrandPharma

News from Asia

Allianz: Reported AI losses understate the true risk and are only the tip of the iceberg

Allianz Commercial analysis highlights emerging and interconnected risks and claims scenarios related to global AI adoption in businesses.

APEC Gathering Fulfills Shenzhen Vendor’s 25-Year Global Friendship Wish

SHENZHEN, CHINA — Media OutReach Newswire – 19 November 2026 – Amid the ongoing 33rd APEC Economic Leaders' Meeting hosted in Shenzhen, a heartwarming story of cross-border friendship has emerged ...

Viet Nam Takes Global Lead in New Climate-Smart Agrifood Partnership Launched at COP31

ANTALYA, TURKEY– Media OutReach Newswire – 19 November 2026 – Viet Nam has taken a significant step in advancing its role in international climate and food systems diplomacy with the launch of a n...

SACOFA Fortifies Connectivity Partnership to Advance Kenyalang Smart City, witnessed by The Premier of Sarawak

SARAWAK, MALAYSIA – Media OutReach Newswire – 19 November 2026 – SACOFA Sdn Bhd (SACOFA) is strengthening its role as the primary backhaul connectivity and telecommunications infrastructure partne...

Dual Engines Driving the Green Transition! WGO Hosts the "Sustainable Finance Award" and "Sustainable Enterprise Award" to Honour Cross-Sector Pioneers

HONG KONG SAR – Media OutReach Newswire – 19 November 2026 – The World Green Organisation (WGO) proudly hosted the presentation ceremony for the "Sustainable Finance Award" and the "Sustainable En...

From the South China Sea to the Aegean: Nansha Seeks Closer Cooperation with Greece in Coastal Sports and Tourism

GUANGZHOU, CHINA – Media OutReach Newswire – 19 November 2026 – During the China-Greece Sports and Cultural Exchange Week held in Athens on November 3, a delegation from Nansha District, Guangzhou...

Yicura BioMed Holds Pre-Launch Preparation Meeting and IDMC Kick-off Meeting for ICVAX-201 Clinical Project

ICVAX® Phase II Clinical Study Enters Key Preparation StageBEIJING, CHINA – Media OutReach Newswire – 19 November 2026 – Yicura BioMed held the Pre-launch Preparation Meeting and the Independent D...

Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI

AACHEN, GERMANY – Newsaktuell – 19 November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, star...

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach Newswire – 19 November 2026 –Thi...

AXS and PayerMax Advance Omnichannel Payment Acceptance for Merchants

SINGAPORE – Media OutReach Newswire – 19 November 2026 – AXS Pte Ltd (AXS), a leading bill management and payment acceptance solutions provider, and PayerMax, a global payment solutions provider, ...

New Research Highlights What Australian Retailers Need to Deliver

New research among Australian SHEIN customers reveals how price comparisons, product quality and customer reviews are shaping purcha...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...